Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis

Table 2 Rates of fibrosis improvement in patients with chronic hepatitis or cirrhosis treated with lamivudine, entecavir, or tenofovir

Ref.	Publication year	Nucleos(t)ide	No. of patients	Treatment duration	Cirrhosis percentage	Improvement ratio of fibrosis
Honkoop et al[8]	1997	LAM (25 mg, 100 mg, 300 mg)	13	6 mo	Not described	No difference in fibrosis was observed
Lai et al[3]	1998	LAM (25 mg, 100 mg, placebo)	358	52 wk	5%	25 mg (n = 72) 5%14
						100 mg (n = 142) 2.5%14
						Placebo (n = 143) 0%14
Suzuki et al[9]	1999	LAM (100 mg)	20	52 wk	0%	All patients (n = 20) 35%1
Dienstag et al[10]	2003	LAM (100 mg, placebo)	63	1 yr + additional 2 yr	17%	Bridging fibrosis (HAI fibrosis score of 3; n = 19)
						63% (1 yr + additional 2 yr)2
						Cirrhosis (HAI fibrosis score of 4; n = 11) 45.5% (1 yr)2; 72.7% (1 yr + additional 2 yr)2
Schiff et al[12]	2008	LAM (100 mg)	245	48 wk	Not described5	ETV (n = 120) HBeAg+ 57%3
		Entecavir (0.5 mg)				HBeAg- 59%3
						LAM (n = 125)
						HBeAg+ 49%3
						HBeAg- 53%3
Chang et al[13]	2010	ETV (0.5 mg)	57	48 wk, long-term (range: 3-7 yr, median: 6 yr)	7%	All patients (n = 57) 32% (48 wk)3
						88% (long-term)3
						Cirrhosis (n = 4)
						100% (long-term)3
Marcellin et al[14]	2012	TDF	348	5 yr	28%	All patients (n = 348)
						51% (5 yr)3
						Cirrhosis (n = 97) 74% (5 yr)3

¹Fibrosis improvement was defined as an HAI fibrosis score decrease of at least 1-point;

²Bridging fibrosis improvement was defined as achieving an HAI fibrosis score of 0 or 1. Cirrhosis improvement was defined as achieving an HAI fibrosis score of 0, 1, or 3;

³Fibrosis improvement was defined as a decrease in the Ishak fibrosis score of at least 1-point;

⁴Approximate value estimated from the published graph;

⁵All patients had advanced fibrosis or cirrhosis (Ishak fibrosis scores of 4-6). LAM: Lamibudine; ETV: Entecavir; TDF: Tenofovir; HBeAg: Hepatitis B e antigen; HAI: Histologic activity index.